ArticleNeuro-oncology2021
Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.
Article in Neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Bevacizumab enhances overall survival in newly diagnosed glioblastoma patients with high COX-2 expression.Scientific reports · 2026Article
- Prognostic value of hypertension timing for survival in glioblastoma patients receiving bevacizumab: a retrospective single centre analysis.Journal of neuro-oncology · 2025Article
- Clinical Translation of HyperpolarizedAJNR. American journal of neuroradiology · 2025Review
- Multisite Benchmark Study for Standardized Relative CBV in Untreated Brain Metastases Using the DSC-MRI Consensus Acquisition Protocol.AJNR. American journal of neuroradiology · 2025Article
- Current trends in the characterization and monitoring of vascular response to cancer therapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Application of Delta T1 maps for quantitative and objective assessment of extent of resection and survival prediction in glioblastoma.Neurosurgery practice · 2024Article
- The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment.Journal of neuro-oncology · 2024Article
- Advanced MR Techniques for Preoperative Glioma Characterization: Part 1.Journal of magnetic resonance imaging : JMRI · 2023Review
- Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.Signal transduction and targeted therapy · 2023Review
- Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625.Frontiers in oncology · 2023Article
- Standardized brain tumor imaging protocols for clinical trials: current recommendations and tips for integration.Frontiers in radiology · 2023Review
- Federated learning enables big data for rare cancer boundary detection.Nature communications · 2022Article
- Dynamic Contrast-Enhanced Ultrasound Modeling of an Analog to Pseudo-Diffusivity in Intravoxel Incoherent Motion Magnetic Resonance Imaging.IEEE transactions on medical imaging · 2022Article
- Review
- High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques.Frontiers in oncology · 2022Review
- Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.Journal of neuro-oncology · 2021Article
- In search of predictive and response markers in antiangiogenic therapy of glioblastoma.Neuro-oncology · 2021Article
- Review
- Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastoma.Neuro-oncology advancesArticle
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundIn Radiation Therapy Oncology Group (RTOG) 0825, a phase III trial of standard therapy with bevacizumab or without (placebo) in newly diagnosed glioblastoma, 44 patients underwent dynamic contrast enhanced (DCE) and/or dynamic susceptibility contrast (DSC) MRI in the American College of Radiology Imaging Network (ACRIN) trial 6686. The association between early changes in relative cerebral blood volume (rCBV) and volume transfer constant (Ktrans) with overall survival (OS) was evaluated.
methodsMRI was performed at postop baseline (S0), immediately before (S1), 1 day after (S2), and 7 weeks after (S3) bevacizumab or placebo initiation. Mean normalized and standardized rCBV (nRCBV, sRCBV) and Ktrans were measured within contrast-enhancing lesion. Wilcoxon rank sum tests compared parameter changes from S1-S2 and S1-S3. Association with OS and progression-free survival (PFS) were determined using Kaplan-Meier and log-rank tests. Treatment response for groups stratified by pretreatment nRCBV (S0, S1) was explored. The intraclass correlation coefficient and repeatability coefficient for the placebo arm (S1-S2) were used to assess repeatability.
resultsEvaluable were 27-36 datasets per time point. Significant differences between treatment arms were found for changes in nRCBV and sRCBV from S1-S2 and S1-S3, and in Ktrans for S1-S3. Improved PFS (P = 0.05) but not OS (P = 0.46) was observed. High pretreatment rCBV predicted improved OS for bevacizumab-treated patients. Based on the intraclass correlation coefficient, sRCBV (0.92) was more repeatable than nRCBV (0.71) and Ktrans (0.75), consistent with repeatability coefficient values.
conclusionsBevacizumab significantly changes rCBV but not Ktrans as early as 1 day posttreatment in newly diagnosed glioblastoma unrelated to outcomes. Improvements in clinical trial design to maximize rCBV benefit are indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.